Kolexia
Arnulf Bertrand Hématologie
Arnulf Bertrand
Hématologie
Hôpital Saint-Louis
Paris, France
324 Activités
19 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Amyloïdose Amylose à chaine légère d'immunoglobuline Paraprotéinémies Macroglobulinémie de Waldenström Récidive tumorale locale Maladies du rein Lymphomes

Collaborateurs

Voir plus
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Leleu Xavier
Leleu Xavier
Hôpital La Miletrie, Poitiers, France
Karlin Lionel
Karlin Lionel
Hôpital Lyon Sud, Pierre-Bénite, France
Royer Bruno
Royer Bruno
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
Janssen
43 collaboration(s)
Dernière en 2023
Amgen
24 collaboration(s)
Dernière en 2023
Celgene
17 collaboration(s)
Dernière en 2023
Sanofi
12 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
KarMMa-9: A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
Essai Clinique (BMS)   18 mars 2024
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma: An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma
Essai Clinique (Janssen)   11 mars 2024
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
The Lancet. Haematology   04 mars 2024
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Essai Clinique (Pfizer)   01 mars 2024
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Essai Clinique (Janssen)   27 février 2024
Dual chimeric antigen receptor T cells targeting CD38 and SLAMF7 with independent signalling demonstrate preclinical efficacy and safety in Multiple Myeloma.
Cancer immunology research   30 janvier 2024
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody: A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Essai Clinique (GSK)   16 décembre 2023
Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series.
Blood   14 décembre 2023
Journée annuelle de la Plateforme d’expertise maladies rares Paris Nord - 24/11/23
Youtube @ AP-HP. Nord - Université Paris Cité   01 décembre 2023
Bulles hémorragiques intrabuccale isolées révélant une amylose AL
Journées dermatologiques de Paris 2023   01 décembre 2023